Biomarker-driven patient selection for early clinical trials
R Dienstmann, J Rodon… - Current opinion in …, 2013 - journals.lww.com
R Dienstmann, J Rodon, J Tabernero
Current opinion in oncology, 2013•journals.lww.comAfter recent success stories with therapies targeting driver molecular aberrations in
genetically defined tumor subtypes, innovative trials based on strong biological hypotheses
are expected to bring further excitement to the field. Tumor heterogeneity and clonal
evolution of the diverse populations of cancer cells during cancer progression, influenced by
the effects of systemic treatments, will have to be taken into consideration in the scenario of
drug development.
genetically defined tumor subtypes, innovative trials based on strong biological hypotheses
are expected to bring further excitement to the field. Tumor heterogeneity and clonal
evolution of the diverse populations of cancer cells during cancer progression, influenced by
the effects of systemic treatments, will have to be taken into consideration in the scenario of
drug development.
Summary
After recent success stories with therapies targeting driver molecular aberrations in genetically defined tumor subtypes, innovative trials based on strong biological hypotheses are expected to bring further excitement to the field. Tumor heterogeneity and clonal evolution of the diverse populations of cancer cells during cancer progression, influenced by the effects of systemic treatments, will have to be taken into consideration in the scenario of drug development.
Lippincott Williams & Wilkins